Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAD | P27708 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8739588 | 0.82 | GAA (0.42) | GAAALDH1A1HTTITGB1ITGA4 | |
| SCHEMBL9688310 | 0.82 | GAA (0.42) | GAAALDH1A1HTTITGB1ITGA4 | |
| SCHEMBL15505791 | 0.79 | FOLH1 (0.42) | CADFOLH1ALDH1A1TSHR | |
| SCHEMBL29094782 | 0.78 | CAD (0.44) | CADFOLH1TSHR | |
| SCHEMBL11885262 | 0.77 | GAA (0.38) | GAAALDH1A1HTTCASP1L3MBTL1 | |
| SCHEMBL19393329 | 0.77 | GAA (0.38) | GAAALDH1A1HTTCASP1L3MBTL1 | |
| SCHEMBL28750770 | 0.76 | FOLH1 (0.56) | FOLH1CA12CA1CA2CA9 | |
| SCHEMBL12890787 | 0.76 | ALOX15 (0.37) | GAAALDH1A1HTTTSHRITGB1 | |
| SCHEMBL22757732 | 0.75 | TLR2 (0.36) | GAAALDH1A1HTTCASP1USP2 | |
| SCHEMBL18130944 | 0.74 | CYP1A2 (0.55) | GAAALDH1A1HTTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090142338-A1 | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions | CUREDM, INC. (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142338-A1 | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions | IAPP, RNASE1, AMY2A | CAD 4035/4885FOLH1 1147/4885GAA 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.